The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival
Abstract
Median survival time of nonresectable hilar bile duct cancer is only 4 to 6 months owing to tumor spread in the biliary tree, refractory cholestasis, and sepsis or liver failure. We explored whether local photodynamic therapy of nonresectable bile duct cancer could improve survival. A sample size of 23 patients is required to detect an increase in 6-month survival rate from less than 50% to greater than 70% in a single-arm phase-II trial with a statistical power of 80% (Fleming’s single step procedure; α = 0.05). Twenty-three consecutive patients (8 women, 15 men; 67 ± 14 years) with nonresectable bile duct cancer (Bismuth type III n = 2, type IV n = 21) were treated with photodynamic therapy and biliary endoprosthesis. Photofrin (QLT Pharmaceuticals, Vancouver, Canada) (2 mg/kg body weight intravenously) was photoactivated after 1 to 4 days with laser light (630 nm; 242 J/cm 2) via endoscopic retrograde access. The 6-month survival rate was 91% after diagnosis and 74% after start of photodynamic therapy (30-day mortality rate was 4%) at a median follow-up time of 10.3 months after diagnosis. Causes of death were tumor progression (n = 9) and bacterial infections (n = 4). The median rate of local tumor response was 74%, 54%, 29%, and 67% after the first, second, third, fourth, and fifth photodynamic therapy. Time to progression ranged from 3 to 8 months. All patients, except 1 with diffuse liver metastases, improved in cholestasis, performance, and quality of life. Photodynamic therapy can prevent tumor occlusion of hilar bile ducts. The apparent benefit in survival time should be confirmed in a controlled trial versus palliation by endoprosthesis only.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of naloxone infusions for the pruritus of chronic cholestasis
Bergasa, N. V., Talbot, T. L., Alling, D. W., Schmitt, J. M., Walker, E. C., Baker, B. L., Korenman, J. C., Park, Y., Hoofnagle, J. H., & Jones, E. A. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90102-5 · Cited by 287
Cited by
The present and future role of photodynamic therapy in cancer treatment
Brown, S. B., Brown, E. A., & Walker, I. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01529-3 · Cited by 1,771
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment†
Blechacz, B., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22310 · Cited by 681
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study
Ortner, M. E. J., Caca, K., Berr, F., Liebetruth, J., Mansmann, U., Huster, D., Voderholzer, W., Schachschal, G., Mössner, J., & Lochs, H. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.015 · Cited by 608
Self-citationPalliation of Nonresectable Bile Duct Cancer: Improved Survival After Photodynamic Therapy
Zoepf, T., Jakobs, R., Arnold, J. C., Apel, D., & Riemann, J. F. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00318.x · Cited by 356
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009
Aljiffry, M., Walsh, M. J., & Molinari, M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4240 · Cited by 286
Metadata
- Authors
- Berr, F., Wiedmann, M., Tannapfel, A., Halm, U., Kohlhaw, K. R., Schmidt, F., Wittekind, C., Hauss, J., & Mössner, J.
- Venue
- Hepatology
- Published
- 2000-02
- Volume
- 31
- Issue
- 2
- Pages
- 291-298
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1999756447
- Cited by
- 199
- References
- 1
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival. https://app.cochat.ai/papers/10.1002/hep.510310205
- The paper
- Berr, F., Wiedmann, M., Tannapfel, A., Halm, U., Kohlhaw, K. R., Schmidt, F., Wittekind, C., Hauss, J., & Mössner, J. (2000). Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival. Hepatology. https://doi.org/10.1002/hep.510310205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.